2 Department of Medicine, Institute Jules Bordet, University Libre Brussels,
|
|
- Rosanna Small
- 8 years ago
- Views:
Transcription
1 Original Article Health-Related Quality of Life of Patients With Advanced Breast Cancer Treated With Everolimus Plus Exemestane Versus Placebo Plus Exemestane in the Phase 3, Randomized, Controlled, BOLERO-2 Trial Howard A. Burris, III, MD 1 ; Fabienne Lebrun, MD 2 ; Hope S. Rugo, MD 3 ; J. Thaddeus Beck, MD 4 ; Martine Piccart, MD, PhD 2 ; Patrick Neven, MD, PhD 5 ; Jose Baselga, MD, PhD 6 ; Katarina Petrakova, PhD 7 ; Gabriel N. Hortobagyi, MD 8 ; Anna Komorowski, MD 9 ; Edmond Chouinard, MD 10 ; Robyn Young, MD 11 ; Michael Gnant, MD 12 ; Kathleen I. Pritchard, MD 13 ; Lee Bennett, MS 14 ; Jean-Francois Ricci, PhD 15 ; Hounayda Bauly, PhD 16 ; Tetiana Taran, MD 17 ; Tarek Sahmoud, MD, PhD 17 ; and Shinzaburo Noguchi, MD 18 BACKGROUND: The randomized, controlled BOLERO-2 (Breast Cancer Trials of Oral Everolimus) trial demonstrated significantly improved progression-free survival with the use of everolimus plus exemestane (EVE þ EXE) versus placebo plus exemestane (PBO þ EXE) in patients with advanced breast cancer who developed disease progression after treatment with nonsteroidal aromatase inhibitors. This analysis investigated the treatment effects on health-related quality of life (HRQOL). METHODS: Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) questionnaire, HRQOL was assessed at baseline and every 6 weeks thereafter until disease progression and/or treatment discontinuation. The 30 items in 15 subscales of the QLQ-C30 include global health status wherein higher scores (range, 0-100) indicate better HRQOL. This analysis included a protocol-specified time to definitive deterioration (TDD) analysis at a 5% decrease in HRQOL versus baseline, with no subsequent increase above this threshold. The authors report additional sensitivity analyses using 10-point minimal important difference decreases in the global health status score versus baseline. Treatment arms were compared using the stratified log-rank test and Cox proportional hazards model adjusted for trial stratum (visceral metastases, previous hormone sensitivity), age, sex, race, baseline global health status score and Eastern Cooperative Oncology Group performance status, prognostic risk factors, and treatment history. RESULTS: Baseline global health status scores were found to be similar between treatment groups (64.7 vs 65.3). The median TDD in HRQOL was 8.3 months with EVE þ EXE versus 5.8 months with PBO þ EXE (hazard ratio, 0.74; P ¼.0084). At the 10- point minimal important difference, the median TDD with EVE þ EXE was 11.7 months versus 8.4 months with PBO þ EXE (hazard ratio, 0.80; P ¼.1017). CONCLUSIONS: In patients with advanced breast cancer who develop disease progression after treatment with nonsteroidal aromatase inhibitors, EVE þ EXE was associated with a longer TDD in global HRQOL versus PBO þ EXE. Cancer 2013;119: VC 2013 American Cancer Society. KEYWORDS: advanced breast cancer, everolimus, exemestane, health-related quality of life, hormone receptor-positive. INTRODUCTION Everolimus (EVE) is a mammalian target of rapamycin inhibitor with direct anticancer effects. In preclinical and clinical studies, EVE demonstrated that mammalian target of rapamycin inhibition can enhance the efficacy of endocrine therapy, including exemestane (EXE). 1-3 The phase 3 BOLERO-2 (Breast Cancer Trials of Oral Everolimus) trial was designed to evaluate the efficacy and safety of EVE þ EXE versus placebo (PBO) þ EXE in postmenopausal women with hormone Corresponding author: Howard A. Burris, III, MD, Sarah Cannon Research Institute, 3322 West End Ave, Suite 900, Nashville, TN 37203; Fax: (615) ; howard.burris@scresearch.net 1 Drug Development Program, Sarah Cannon Research Institute, Nashville, Tennessee; 2 Department of Medicine, Institute Jules Bordet, University Libre Brussels, Brussels, Belgium; 3 Division of Hematology and Oncology, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California; 4 Highlands Oncology Group, Fayetteville, Arkansas; 5 Department of Gynecologic Oncology, Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven, Belgium; 6 Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, New York; 7 Department of Medical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic; 8 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; 9 Hematology Oncology Associates of Rockland, Nyack, New York; 10 Department of Medical Oncology, Cambridge Memorial Hospital, Cambridge, Ontario, Canada; 11 Breast Cancer Center of Excellence, The Center for Cancer and Blood Disorders, Fort Worth, Texas; 12 Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; 13 Department of Oncology, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; 14 RTI Health Solutions, Research Triangle Park, North Carolina; 15 Wellmera AG, Basel, Switzerland; 16 Novartis Pharma AG, Basel, Switzerland; 17 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; 18 Department of Breast and Endocrine Surgery, Osaka University, Osaka, Japan We thank Marithea Goberville, PhD, ProEd Communications, Inc, for medical editorial assistance with this article. Previously presented in abstract form as Beck JT, Rugo HS, Burris HA, et al. BOLERO-2: health-related quality of life in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane. Presented at the 2012 American Society of Clinical Oncology Annual Meeting; June 1-5, 2012; Chicago, IL [abstract]. J Clin Oncol. 2012;30(suppl). Abstract 539. DOI: /cncr.28010, Received: October 30, 2012; Revised: December 5, 2012; Accepted: December 26, 2012, Published online February 15, 2013 in Wiley Online Library (wileyonlinelibrary.com) 1908 Cancer May 15, 2013
2 QOL in Advanced Breast Cancer/Burris et al receptor-positive advanced breast cancer who developed disease progression after treatment with nonsteroidal aromatase inhibitors (NSAIs; letrozole or anastrozole). 4 Data from an interim analysis at 7 months of follow-up demonstrated that EVE þ EXE significantly improved the primary endpoint of progression-free survival (PFS) versus PBO þ EXE (hazard ratio [HR], 0.43; P <.001) based on local investigator assessment. 4 Median durations of PFS were 6.9 months and 2.8 months, respectively. The PFS benefit was confirmed at 12.5 months and 18 months of median follow-up. 5,6 Adverse events were consistent with the safety profile of EVE. 6 The findings from this trial supported the recent approval in the United States and Europe of EVE þ EXE for the treatment of postmenopausal women with hormone receptor-positive advanced breast cancer who developed disease progression while receiving treatment with NSAIs. 7,8 Treatment-related toxicities combined with often painful and debilitating metastases resulting from disease progression can erode health-related quality of life (HRQOL) Therefore, in addition to clinical benefit, providing palliation and maximizing HRQOL remain the key goals of treating patients with advanced breast cancer. 13 Studies of HRQOL can aid in treatment selection and provide information regarding the impact of disease progression on patients lives. 14,15 Furthermore, evaluation of HRQOL concerns such as fatigue, pain, and anxiety, as well as the impact of disease on physical and social functioning, can augment the overall risk:benefit analysis, and HRQOL is now regarded as an important outcome in clinical cancer trials. 14,16,17 These outcomes are especially important in patients with hormone receptor-positive advanced breast cancer, in whom endocrine therapy options after disease progression with NSAI treatment (eg, fulvestrant and EXE) might provide limited therapeutic benefit, but have relatively low toxicity. 18 In the BO- LERO-2 trial, time to HRQOL deterioration was a secondary objective because it was essential to determine the impact of EVE þ EXE versus PBO þ EXE on HRQOL. In the current study, we report the results of that HRQOL analysis. MATERIALS AND METHODS Patients and Study Design The study design for BOLERO-2 has been described previously. 4 The population comprised postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2 (HER2) negative, metastatic or locally advanced breast cancer who developed disease progression despite prior treatment with anastrozole or letrozole. All patients provided informed consent. In this multicenter, double-blind, randomized, placebo-controlled trial, all patients received EXE (at a dose of 25 mg/day) and were randomized 2:1 to treatment with EVE (at a dose of 10 mg/day) or matching PBO. 4 Randomization was stratified by the presence of visceral metastasis (yes vs no) and sensitivity to prior hormonal therapy (yes vs no). 4 Treatment continued until disease progression, the development of unacceptable toxicity, or withdrawal of patient consent. The primary endpoint was PFS, as assessed by investigators. Overall survival, overall response rate, clinical benefit rate, time to deterioration of Eastern Cooperative Oncology Group (ECOG) performance status, safety, and HRQOL were secondary endpoints. This analysis includes HRQOL outcomes; the results of all other endpoints have been reported previously. 5,6 HRQOL Assessment HRQOL was evaluated at baseline and every 6 weeks thereafter until disease progression and/or discontinuation using version 3.0 of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). All questionnaires were completed at the study center before disease assessment. The questionnaire consists of 30 items arranged in 15 subscales, including a global health status/ QOL scale; higher scores for this scale (range, 0-100) indicate better HRQOL. 19 Statistical Analysis All HRQOL analyses were performed on the full analysis set (N ¼ 724). Partially completed questionnaires were included if the data were sufficient to calculate the global health status/qol domain subscale score. A deterioration event was defined as a 5% decrease in HRQOL relative to baseline. Protocol-specified time to definitive deterioration (TDD) in the global health status score was defined as a 5% HRQOL decrease relative to baseline, with no subsequent increase above this threshold. The 5% decrease in HRQOL from baseline criterion was selected based on previously established thresholds for minimal important differences (MID) in QOL from the perspective of the patient. 20 This criterion for TDD was less stringent than previously published MID values for global health status Generally established and accepted MID values for global health status range from 5 to 10 points. Therefore, a sensitivity analysis was performed to assess the larger, 10-point MID decrease in global health status score compared with baseline; this criterion has been Cancer May 15,
3 Original Article TABLE 1. ECOG Performance Status Score EVEþEXE, % (n ¼ 485) PBOþEXE, % (n ¼ 239) Abbreviations: ECOG, Eastern Cooperative Oncology Group; EVE, everolimus; EXE, exemestane; PBO, placebo. Reprinted with permission from Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. NEnglJMed.2012;366: CopyrightVC 2011 Massachusetts Medical Society. Reprinted with permission from the Massachusetts Medical Society. 4 validated for EORTC QLQ-C30 in other studies TDD in global health status for each of the definitions was calculated using Kaplan-Meier estimates and was described using medians and 95% confidence intervals (95% CIs). TDD was compared between the treatment groups using a stratified log-rank test (strata were based on the presence of visceral metastases and sensitivity to hormonal therapy) with a 2-sided type I error rate of 0.05, and a multivariate Cox proportional hazards model adjusted for trial strata (the presence of visceral metastases and sensitivity to hormone therapy), age, sex, race, baseline score and ECOG performance status, prognostic risk factors, and treatment history. If a definitive deterioration event was observed after missing assessments, the event was backdated to the first of the missing assessments before the deterioration (ie, calculated as the last available assessment before the definitive deterioration plus 8 weeks). No other adjustments were made for missing data. Patients who had no definitive deterioration events were censored at the time of the last available assessment. All analyses were conducted using SAS statistical software for Windows (version 9.2; SAS Institute Inc, Cary, NC). RESULTS Patient Characteristics and Disposition Between June 2009 and January 2011, 724 women across 189 centers in 24 countries were randomized to study treatments (485 in the EVE þ EXE arm and 239 in the PBO þ EXE arm). 4 The treatment arms were well balanced for patient and disease characteristics, including ECOG performance status score. 4 Notably, the majority of patients in both the EVE þ EXE and PBO þ EXE treatment arms had an ECOG performance status score of 0 (60% vs 59%, respectively) (Table 1). At a median follow-up of 18 months, 91 patients continued to receive study treatment: 81 (17%) in the EVE þ EXE arm and 10 (4%) in the PBO þ EXE arm. 6 The median duration of treatment exposure was 23.9 weeks for EVE and 29.5 weeks for EXE in the EVE þ EXE arm and 13.4 weeks for PBO and 14.1 weeks for EXE in the PBO þ EXE arm. Most patients in the EVE þ EXE and PBO þ EXE treatment arms discontinued treatment because of disease progression (62% vs 89%, respectively). Other reasons for discontinuation included adverse events (10% vs 3%, respectively) and consent withdrawal (9% vs 3%, respectively). Efficacy and Safety Data from a preplanned analysis at a median follow-up of 18 months demonstrated that EVE þ EXE more than doubled PFS versus PBO þ EXE. 6 However, EVE þ EXE was associated with a higher incidence of adverse events than PBO þ EXE, with the most common grade 3 or 4 adverse events (graded using the NCI CTCAE version 3.0) being stomatitis, hyperglycemia, and fatigue. 6 Questionnaire Completion Rates At baseline, questionnaires were completed by 455 patients (93.8%) in the EVE þ EXE arm and 224 patients (93.7%) in the PBO þ EXE arm. Data are presented through 48 weeks only, given a substantial decrease in subsequent data availability in both treatment arms. Questionnaire compliance was > 80% through week 48 and was not found to be markedly different between the treatment arms (Fig. 1a). Questionnaire completion rates decreased from baseline to week 48 (Fig. 1b), mainly because of disease progression and subsequent removal from the study. Compared with baseline, completion rates from weeks 12 through 48 were higher in the EVE þ EXE arm versus the PBO þ EXE arm (Fig. 1b). TDD in Global Health Status Baseline global health status scores were similar between the EVE þ EXE and PBO þ EXE arms (64.7 vs 65.3, respectively; difference, 0.7 [95% CI, 4.3 to 3.0]). At a median follow-up of 18 months, the cumulative percentages of patients with a definitive deterioration in global health status treated with EVE þ EXE versus PBO þ EXE were comparable for both TDD definitions (Table 2). At a 5% change from baseline, 49% of patients in the EVE þ EXE arm versus 44% of patients in the PBO þ EXE arm had a definitive deterioration event, and death occurred in 3% of patients in each treatment arm. At a 10-point MID, definitive deterioration rates were 39% in the EVE þ EXE arm versus 30% in the PBO þ EXE arm, and death rates were 3% and 5%, respectively Cancer May 15, 2013
4 QOL in Advanced Breast Cancer/Burris et al Figure 2. Time to definitive deterioration (TDD) for European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) global health status is shown, indicating a 5% change from baseline. HR indicates hazard ratio; 95% CI, 95% confidence interval; EVE, everolimus; EXE, exemestane; PBO, placebo; QOL, quality of life. Figure 1. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) global health status questionnaire results for (a) compliance and (b) completion rates at baseline and follow-up visits are shown. (a) Percentage compliance rates were calculated based on the number of on-study patients in each treatment arm at every visit. (b) Percentage completion rates were calculated based on the intent-to-treat population in each treatment arm. EVE indicates everolimus; EXE, exemestane; PBO, placebo. At 5% change from baseline, EVE þ EXE was associated with longer TDD in global health status versus PBO þ EXE. The median TDD was 8.3 months (95% CI, 7.0 months-9.7 months) in the EVE þ EXE arm versus 5.8 months (95% CI, 4.2 months-7.2 months) in the PBO þ EXE arm (Fig. 2). This translated into a 26% reduction in the risk of definitive deterioration with EVE þ EXE (HR, 0.74; 95% CI, [P ¼.0084 by the log-rank test]). Using the 10-point MID, the median TDD remained longer in the EVE þ EXE arm versus the PBO þ EXE arm (11.7 months [95% CI, 9.7 months months] vs 8.4 months [95% CI, 6.6 months-12.5 months], respectively) (HR, 0.8; 95% CI, [P ¼.1017 by the log-rank test]) (Fig. 3). The P value for TDD using a 5% change from baseline was found to be more significant than the P value for TDD using a 10- point MID (.0084 vs.1017, respectively), although the magnitudes of effect in terms of HR and difference in Figure 3. Time to definitive deterioration (TDD) for European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) global health status is shown, with a minimal important difference of 10. HR indicates hazard ratio; 95% CI, 95% confidence interval; EVE, everolimus; EXE, exemestane; PBO, placebo; QOL, quality of life. TDD were similar. This may be because of the number of patients for whom censoring was greater based on the 10- point MID criteria for TDD. Regardless of the definition used (a 5% change from baseline or a 10-point MID), no statistically significant differences were observed with regard to the TDD of global health status for the majority of the prospectively defined patient-related and disease-related variables (Fig. 4); 1 exception was baseline ECOG performance status: in the overall trial, patients with a baseline ECOG performance status of 1 or 2 were found to have an increased risk of deterioration in global health status versus patients with a baseline performance status of 0. In addition, TDD of global health status was analyzed for subsets defined by baseline ECOG performance Cancer May 15,
5 Original Article Figure 4. Risk of definitive deterioration in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) global health status (GHS) by subgroups is shown, based on a 5% change from baseline and a 10-point minimal important difference (MID). Only patients with a valid baseline score were included, and only extended model data were reported. The hazard ratios (HRs) represent multiplicative increases in the risk of definitive deterioration per 1- unit increase in age or GHS. EVE, everolimus; EXE, exemestane; PBO, placebo; mets, metastases; ECOG PS, Eastern Cooperative Oncology Group performance status; PgR, progesterone receptor; 95% CI, 95% confidence interval. status (0 vs 1-2) and age (< 65 years vs 65 years). Kaplan-Meier estimates indicated a longer median TDD for EVE þ EXE versus PBO þ EXE by both definitions in patients with an ECOG performance status of 1 or 2 (5% change from baseline: 8.2 months vs 4.1 months [P ¼.0076]; 10-point MID: 9.7 months vs 6.0 months [P ¼.0342]) and in patients aged < 65 years (5% change from baseline: 9.6 months vs 5.6 months [P ¼.0130]; 10- point MID: 12.5 months vs 9.7 months [P ¼.0353]). Cox proportional hazards models adjusted for study strata (the presence of visceral metastases and sensitivity to hormone therapy) also demonstrated a longer median TDD for EVE þ EXE versus PBO þ EXE in patients with an ECOG performance status of 1 or 2 (5% change from baseline: HR, 0.58 [95% CI, ]; 10-point MID: HR, 0.61 [95% CI, ]) and in those aged 1912 Cancer May 15, 2013
6 QOL in Advanced Breast Cancer/Burris et al TABLE 2. Definitive Deterioration in EORTC QLQ-C30 Global Health Status Definition of Definitive Deterioration 5% Change From Baseline MID¼10 Characteristic EVEþEXE (n ¼ 485) PBOþEXE (n ¼ 239) EVEþEXE (n ¼ 485) PBOþEXE (n ¼ 239) Deterioration event, no. (%) 254 (52) 113 (47) 202 (42) 84 (35) Definitive deterioration 240 (49) 105 (44) 188 (39) 71 (30) Death 14 (3) 8 (3) 14 (3) 13 (5) Censored, no. (%) 231 (48) 126 (53) 283 (58) 155 (65) Median TDD (95% CI), mo 8.3 ( ) 5.8 ( ) 11.7 ( ) 8.4 ( ) P Abbreviations: 95% CI, 95% confidence interval; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EVE, everolimus; EXE, exemestane; MID, minimal important difference; PBO, placebo; TDD, time to definitive deterioration. < 65 years (5% change from baseline: HR, 0.70 [95% CI, ]; 10-point MID: HR, 0.70 [95% CI, ]). No differences in the median TDD were observed between treatment groups by either analysis method in patients with an ECOG performance status of 0 or those aged 65 years. DISCUSSION The current study assessed the effects of treatment with EVE þ EXE versus PBO þ EXE on patients HRQOL using the EORTC QLQ-C30, which is one of the most common and well-developed/validated instruments for measuring HRQOL in oncology trials. 15,24 The EORTC QLQ-C30 global health status scores were analyzed based on 2 definitions of TDD: a protocol-specified 5% change from baseline and a MID of a 10-point change from baseline that was found to be relevant in other cancer populations. 21 With the 5% change from baseline, the TDD of global health status was found to be prolonged in patients who received EVE þ EXE versus those receiving PBO þ EXE (8.3 months vs 5.8 months, respectively; P ¼.0084). Using the 10-point MID assessment, the difference in TDD between the EVE þ EXE and PBO þ EXE arms (11.7 months vs 8.4 months, respectively; P ¼.1017) was of a magnitude similar to that observed with the 5% TDD analysis, with more profound benefits noted in patients with a baseline ECOG performance status of 1 or 2 and those aged < 65 years. Unadjusted cumulative definitive deterioration event rates were slightly higher in the EVE þ EXE treatment arm versus the PBO þ EXE arm, although the TDD of global health status was longer with EVE þ EXE. This is likely because of the earlier occurrence of disease progression in patients treated with PBO þ EXE compared with those receiving EVE þ EXE, and the resultant longer follow-up of patients in the EVE þ EXE arm. Together, these results indicate that, at a minimum, adding EVE to EXE does not have a deleterious effect on HRQOL versus the use of PBO þ EXE in patients with hormone receptor-positive advanced breast cancer who develop disease progression after initial treatment with NSAIs. The improvement in the TDD of global health status with EVE þ EXE was demonstrated despite a higher incidence of grade 3 or 4 toxicities and discontinuations because of adverse events reported in this treatment arm. 6 Therefore, it is possible that other factors, such as clinical benefit, may have contributed to this longer TDD noted in global health status in the EVE þ EXE arm. In the BOLERO-2 trial, at a median follow-up of 18 months, EVE þ EXE more than doubled the median PFS 6 and resulted in higher clinical benefit rates compared with PBO þ EXE. 5 Furthermore, lower overall mortality rates were reported in the EVE þ EXE treatment arm versus the PBO þ EXE arm; this difference was not statistically significant and mature survival data were still awaited at the time of last follow-up. 6 In addition, at a median follow-up of 18 months, the EVE þ EXE treatment arm was associated with much lower discontinuation rates because of disease progression (62% vs 89%), and a greater percentage of patients in this arm were still receiving treatment at the time of last follow-up (17% vs 4%). 6 Protocoldefined adverse event management strategies may also have helped limit HRQOL deterioration. 25 In contrast to these findings, although second-line endocrine therapies such as EXE and fulvestrant have not been associated with worsening HRQOL, to the best of our knowledge they have provided only limited clinical efficacy in the advanced breast cancer setting after NSAI therapy. These observations suggest that significantly improved clinical efficacy outcomes may have positively impacted HRQOL in the EVEþEXE arm despite higher incidence of grade 3 or 4 toxicities observed with EVEþEXE. Cancer May 15,
7 Original Article As with most HRQOL studies, a limitation of the current study is the number of missing questionnaires. Although compliance with questionnaire completion was high (> 80%) in both treatment arms, data availability decreased over time because of study discontinuations subsequent to progressive disease (because HRQOL was not assessed after disease progression). Patients who did not meet definitive deterioration criteria before disease progression were censored. Given that a greater percentage of patients developed disease progression earlier in the PBO þ EXE arm compared with the EVE þ EXE arm, and that HRQOL typically deteriorates after disease progression, 26 this analysis is likely conservative in terms of the benefit of EVE þ EXE. Although effective treatments for breast cancer are expected to maintain or improve the patient s HRQOL, as has been demonstrated with EVE þ EXE in the current study, mixed effects on HRQOL have been observed in the setting of advanced breast cancer. 27 Some studies investigating combined targeted therapies (eg, lapatinib plus trastuzumab vs lapatinib alone) reported small, nonsignificant HRQOL benefits, 28 but these effects are inconsistent. In other studies, adverse events attributable to breast cancer treatment (such as the TEX [epirubicin, paclitaxel, and capecitabine] regimen) had a detrimental impact on HRQOL. 29 Symptom clusters such as pain, fatigue, insomnia, and mood disturbances are prevalent in patients after cancer treatment, particularly chemotherapy and radiotherapy, and can adversely affect QOL and functional status. 30 In addition, decreases in QOL may also be exacerbated by the route of administration of chemotherapy, 31 as well as the dose intensity of the regimen. 32 Time-to-progression or PFS benefits observed with the addition of targeted agents to chemotherapy and/or endocrine therapy (eg, capecitabine or letrozole plus lapatinib vs either treatment alone) generally have neutral effects at best on QOL, 14,33 most likely because the delay in disease progression is offset by an increased burden of adverse events. Given that HRQOL might also be prognostic in women with metastatic breast cancer, 34,35 it is essential to take into account the potential negative effects of treatment on HRQOL, and the HRQOL data from BOLERO-2 are reassuring in this context. In the BOLERO-2 trial, postmenopausal women with hormone receptor-positive advanced breast cancer who developed disease progression after initial treatment with NSAI and then received the all-oral combination of EVE þ EXE experienced a longer TDD in their global HRQOL than those in the PBO þ EXE treatment arm. This was particularly evident in younger patients and those with a reduced ECOG performance status at baseline. Together with significant improvements in clinical efficacy outcomes, these HRQOL findings provide added support for the benefit of EVE þ EXE in this patient population. FUNDING SUPPORT Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation. CONFLICT OF INTEREST DISCLOSURES Dr. Baselga has acted as a consultant for Novartis. Dr. Bauly is an employee of Novartis. Mr. Bennett has been employed by Novartis as a contracted analyst while an employee of RTI Health Solutions. Dr. Chouinard has received research support and advisory board honoraria from Novartis. Dr. Gnant has acted as a consultant for Novartis and Merrion and as a member of the advisory board for Novartis, AstraZeneca, GlaxoSmith- Kline, and Amgen and has received research funding from Roche, Sanofi-Aventis, GlaxoSmithKline, Novartis, and AstraZeneca. Dr. Hortobagyi is a member of the BOLERO-2 steering committee and has received research support, honoraria, and reimbursements from Novartis. Dr. Noguchi has received grant support from AstraZeneca, Bristol-Myers Squibb, Chugai, GlaxoSmithKline, Novartis, Pfizer, Sanofi-Aventis, and Takeda and honoraria from AstraZeneca, Chugai, GlaxoSmithKline, Novartis, Pfizer, Sanofi-Aventis, and Takeda. Dr. Piccart has received support from Novartis. Dr. Pritchard has acted as a consultant for Sanofi-Aventis, AstraZeneca, Roche, Pfizer, Ortho Biotech, YM Biosciences, Amgen, GlaxoSmithKline, and Novartis; has received research funding (directly or indirectly) from the National Cancer Institute of Canada Clinical Trials Group and contracted with AstraZeneca, YM Biosciences, Bristol-Myers Squibb, Sanofi-Aventis, Amgen, Ortho Biotech, Pfizer, Glaxo- SmithKline, and Novartis; and received honoraria from Sanofi- Aventis, AstraZeneca, Pfizer, Roche, GlaxoSmithKline, Amgen, and Novartis. She has also provided paid expert testimony for Sanofi-Aventis and AstraZeneca and been a member of the advisory boards of Sanofi-Aventis, AstraZeneca, Ortho Biotech, Roche, Pfizer, Novartis, GlaxoSmithKline, Amgen, and Bayer Schering Pharma. Dr. Ricci has acted as a consultant for Novartis. Dr. Rugo has received research support from Novartis, Pfizer, and Merck. Drs. Sahmoud and Taran are employees of Novartis. Dr. Young has acted as a member of the Speakers Bureau for Celgene and Bristol-Myers Squibb. REFERENCES 1. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2- negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012;30: Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27: Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mtor and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 2005;11: Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366: Cancer May 15, 2013
8 QOL in Advanced Breast Cancer/Burris et al 5. Hortobagyi GN, Piccart M, Rugo H, et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial. Cancer Res. 2011;71(24 suppl 3):105s-106s. Abstract Piccart-Gebhart MJ, Noguchi S, Pritchard KI, et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial. J Clin Oncol. 2012;30(suppl). Abstract Novartis Pharmaceuticals. Afinitor (everolimus) tablets [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; pdf. Accessed June 26, Gotay CC, Lipscomb J, Snyder CF. Reflections on findings of the Cancer Outcomes Measurement Working Group: moving to the next phase. J Natl Cancer Inst. 2005;97: Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(suppl 8): Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22: Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007;13: Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2: Gerber B, Freund M, Reimer T. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int. 2010;107: Zhou X, Cella D, Cameron D, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2þ (ErbB2þ) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat. 2009;117: Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to J Exp Clin Cancer Res. 2008;27: Bottomley A, Therasse P. Quality of life in patients undergoing systemic therapy for advanced breast cancer. Lancet Oncol. 2002;3: Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15: Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26: Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A; on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels, Belgium: European Organisation for Research and Treatment of Cancer; Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR; Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77: Maringwa JT, Quinten C, King M, et al; EORTC PROBE project and the Lung Cancer Group. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Support Care Cancer. 2011;19: Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16: Ringash J, O Sullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. Cancer. 2007;110: Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ. 2002;324: Rugo HS, Pritchard KI, Gnant M, et al. Everolimus (EVE) for postmenopausal women with advanced breast cancer (ABC) refractory to letrozole or anastrozole: long-term efficacy and safety results of the BOLERO-2 trial [abstract]. Eur J Cancer. 2012;48(suppl 1):S116. Abstract Helgeson VS, Tomich PL. Surviving cancer: a comparison of 5-year disease-free breast cancer survivors with healthy women. Psychooncology. 2005;14: Goodwin PJ, Ennis M, Bordeleau LJ, et al. Health-related quality of life and psychosocial status in breast cancer prognosis: analysis of multiple variables. J Clin Oncol. 2004;22: Wu Y, Amonkar MM, Sherrill BH, et al. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2þ metastatic breast cancer. Ann Oncol. 2011;22: Svensson H, Einbeigi Z, Johansson H, Hatschek T, Brandberg Y. Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine). Breast Cancer Res Treat. 2010;123: Cheng KK, Lee DT. Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer. Crit Rev Oncol Hematol. 2011;78: Strada MR, Palumbo R, Bernardo A, et al. Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials. Clin Breast Cancer. 2012;12: Nuzzo F, Morabito A, Gravina A, et al. Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial. BMC Cancer. 2011;11: Sherrill B, Amonkar MM, Sherif B, Maltzman J, O Rourke L, Johnston S. Quality of life in hormone receptor-positive HER-2þ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist. 2010;15: Giese-Davis J, Collie K, Rancourt KM, Neri E, Kraemer HC, Spiegel D. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol. 2011;29: Svensson H, Hatschek T, Johansson H, Einbeigi Z, Brandberg Y. Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer. Med Oncol. 2012;29: Cancer May 15,
Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Everolimus in combination with exemestane hormone therapy for oestrogen receptor positive locally advanced or metastatic
More informationClinical Spotlight in Breast Cancer
2015 European Oncology Congress in Vienna Clinical Spotlight in Breast Cancer Reference Slide Deck Abstract #1815 Impact of Palbociclib Plus Fulvestrant on Global QOL, Functioning, and Symptoms Compared
More informationONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico
ONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico Sequenza ottimale del trattamento Maria Teresa Scognamiglio U.O.C. Clinica Oncologica Chieti-Ortona Chieti 12 novembre 213
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationTreatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University
Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationKanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationStrength of Study End Point(s): Progression-free survival
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Paclitaxel for the First-line Treatment of Metastatic Breast Cancer Drug/Drug Combination: Bevacizumab and
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationIBRANCE is not approved for any indication in any market outside the U.S.
IBRANCE (palbociclib) Fact Sheet IBRANCE (palbociclib) is an oral inhibitor of cyclin-dependent kinases (CDKs) 4 and 6. IBRANCE is indicated in combination with letrozole for the treatment of postmenopausal
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationClinical Trials of Lapatinib in Patients with Brain Metastases. Nancy U Lin, MD Dana Farber Cancer Institute March 1, 2009
Clinical Trials of Lapatinib in Patients with Brain Metastases from HER2+ Breast Cancer Nancy U Lin, MD Dana Farber Cancer Institute March 1, 2009 Background ~1/3 of women with HER2+ MBC develop brain
More information18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationWhat is the optimal sequence of anti-her2 therapy in metastatic breast cancer?
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationOpen Access RESEARCH. Surachat Ngorsuraches 1* and Klangjai Thongkeaw 2
DOI 10.1186/s40064-015-1482-9 RESEARCH Open Access Patients preferences and willingness to pay for postmenopausal hormone receptor positive, HER2 negative advanced breast cancer treatments after failure
More informationSubcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors. 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D.
Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D., FACS Learning Objectives After reading and reviewing this
More informationComparing Immunotherapy with High Dose IL-2 and Ipilimumab
Comparing Immunotherapy with High Dose IL-2 and Ipilimumab Michael K Wong MD PhD FRCPC mike.wong@med.usc.edu Disclosures Speaker s Bureau, Advisory Boards, Consultant: Prometheus Bristol Myers Squibb Novartis
More informationThe NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab.
Cost Effectiveness of Pertuzumab (Perjeta ) in Combination with Trastuzumab and Docetaxel in Adults with HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer Who Have Not Received Previous
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More informationMetastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Carboplatin INDICATION: Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY
More informationLOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT
LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of
More informationAnti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
More informationGuidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer September 3, 2015
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer September 3, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationMiquel Àngel Seguí Palmer
Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with
More informationOne of the most mature trials that examined PROCEEDINGS. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J.
Hormone Therapy in Postmenopausal Women With Breast Cancer * William J. Gradishar, MD ABSTRACT *Based on a presentation given by Dr Gradishar at a roundtable symposium held in Baltimore on June 28, 25.
More informationShould we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,
More informationMechanism Of Action of Palbociclib & PFS Benefit
A Phase II Randomized Controlled Trial of Palbociclib & Tamoxifen/Fulvestrant in Postmenopausal Women and Men With Hormone-Receptor Positive, HER2- Negative Metastatic Breast Cancer (MBC) Protocol Chair:
More informationJ Clin Oncol 30:2718-2724. 2012 by American Society of Clinical Oncology INTRODUCTION
VOLUME 30 NUMBER 22 AUGUST 1 2012 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor Positive,
More informationLAPATINIB-BASED THERAPY FOR WOMEN WITH ADVANCED/ METASTATIC HER2 POSITIVE BREAST CANCER
146 Experimental Oncology 37, 146 150, 2015 (June) Exp Oncol 2015 37, 2, 146 150 LAPATINIB-BASED THERAPY FOR WOMEN WITH ADVANCED/ METASTATIC HER2 POSITIVE BREAST CANCER J. Zekri 1, 2, M. Mokhtar 3, S.M.
More informationQuality of Life Clinical Trials in Patients with Cancer
Quality of Life Clinical Trials in Patients with Cancer Danielle Noreika, MD Medical Director, Inpatient Palliative Services Division of Hematology, Oncology and Palliative Care Virginia Commonwealth University
More informationStudy Design. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D. Ellis Unger, M.D. Ghanshyam Gupta, Ph.D. Chief, Therapeutics Evaluation Branch
BLA: STN 103471 Betaseron (Interferon β-1b) for the treatment of secondary progressive multiple sclerosis. Submission dated June 29, 1998. Chiron Corp. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D.
More informationDecision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
More informationFulvestrant in Heavily Pretreated Metastatic Breast Cancer: Is It Still Effective as a Very Advanced Line of Treatment?
Fulvestrant in Heavily Pretreated Metastatic Breast Cancer: Is It Still Effective as a Very Advanced Line of Treatment? Tamar Safra MD *, Julia Greenberg MD *, Ilan G. Ron MD, Rami Ben Yosef MD, Moshe
More informationClinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
More informationHow valuable is a cancer therapy? It depends on who you ask.
How valuable is a cancer therapy? It depends on who you ask. Comparing and contrasting the ESMO Magnitude of Clinical Benefit Scale with the ASCO Value Framework in Cancer Ram Subramanian Kevin Schorr
More informationBreast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer. Kevin R. Fox, MD University of Pennsylvania
Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer Kevin R. Fox, MD University of Pennsylvania Prevention of Breast Cancer Accepted treatments Tamoxifen (premenopausal
More informationIntroduction Objective Methods Results Conclusion
Introduction Objective Methods Results Conclusion 2 Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma a rare cancer associated with long latency period (i.e. 20 to 40 years),
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationLow dose capecitabine is effective and relatively nontoxic in breast cancer treatment.
1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300
More informationBREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I
BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness
More informationBreast Cancer Treatment Guidelines
Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision
More informationEfficacy analysis and graphical representation in Oncology trials - A case study
Efficacy analysis and graphical representation in Oncology trials - A case study Anindita Bhattacharjee Vijayalakshmi Indana Cytel, Pune The views expressed in this presentation are our own and do not
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationEvaluation of Treatment Pathways in Oncology: An Example in mcrpc
Evaluation of Treatment Pathways in Oncology: An Example in mcrpc Sonja Sorensen, MPH United BioSource Corporation Bethesda, MD 1 Objectives Illustrate selection of modeling approach for evaluating pathways
More informationCytotoxic Therapy in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions
More informationManagement of ER+/HER2- Breast Cancer: New Options, New Insights, Coming Agents
Management of ER+/HER2- Breast Cancer: New Options, New Insights, Coming Agents P. Kelly Marcom, MD Associate Professor Co-Director Breast Cancer Clinical Research NCOA August 23, 2014 Off-Label Use Disclosure(s)
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationCOMPENDIA TRANSPARENCY TRACKING FORM. Sunitinib malate. Metastatic breast cancer, HER2-negative
COMPENDIA TRANPARENCY TRACKING FORM DRUG: unitinib malate INDICATION: Metastatic breast cancer, HER2-negative COMPENDIA TRANPARENCY REQUIREMENT 1 Provide criteria used to evaluate/prioritize the request
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationGilberto de Lima Lopes, MD, MBA, FAMS Chief Medical and Scientific Officer, Oncoclinicas Group Asst. Prof. of Oncology, Johns Hopkins University
Gilberto de Lima Lopes, MD, MBA, FAMS Chief Medical and Scientific Officer, Oncoclinicas Group Asst. Prof. of Oncology, Johns Hopkins University Assoc. Editor ASCO University and JGO Progress Against
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationProstatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationThird-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status
Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 209e214 Original Article Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationClinical Trial Designs for Firstline Hormonal Treatment of Metastatic Breast Cancer
Clinical Trial Designs for Firstline Hormonal Treatment of Metastatic Breast Cancer Susan Honig, M.D. Patricia Cortazar, M.D. Rajeshwari Sridhara, Ph.D. Acknowledgements John Johnson Alison Martin Grant
More informationTransgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO
Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous
More informationIf several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.
General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationIn ELOQUENT-2, Empliciti was evaluated in patients who had received one to three prior
- First and only immunostimulatory antibody approved in the European Union for multiple myeloma - Accelerated assessment and approval based on long-term data from ELOQUENT-2, which evaluated Empliciti
More informationInformation and Insight into Breast Cancer in China. White Paper. by Neesha Suvarna, PhD Consultant, Kantar Health November 2011
White Paper Catalysts driving successful decisions in life sciences. Information and Insight into Breast Cancer in China by Neesha Suvarna, PhD Consultant, Kantar Health November 2011 www.kantarhealth.com
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationClinical Study Report
An Open, Multi-Center, Phase II Clinical Trial to Evaluate Efficacy and Safety of Taxol (), UFT, and Leucovorin in Patients with Advanced Gastric Cancer Clinical Study Report 4F, No. 156, Jiankang Rd.,
More informationWhat s new in prostate cancer research? Highlights of GU-ASCO 2014
review What s new in prostate cancer research? Highlights of GU-ASCO 2014 Cite as: Can Urol Assoc J 2014;8(3-4Suppl2):S8-12. http://dx.doi.org/10.5489/cuaj.2013 Published online April 14, 2014. Abstract
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationDevelopment of Bone Metastases in Men With Prostate Cancer
Development of Bone Metastases in Men With Prostate Cancer Explore the Causes Understand the Consequences Natural History of Prostate Cancer Progression Many prostate tumors may become castrate-resistant
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationF Montemurro 1, G Rondón 2, NT Ueno 2, M Munsell 3, JL Gajewski 2 and RE Champlin 2. Summary:
(2002) 29, 861 866 2002 Nature Publishing Group All rights reserved 0268 3369/02 $25.00 www.nature.com/bmt Breast cancer Factors affecting progression-free survival in hormone-dependent metastatic breast
More informationOptimizing chemotherapy-free survival for the ER/HER2 positive metastatic breast cancer patient
Optimizing chemotherapy-free survival for the ER/HER2 positive metastatic breast cancer patient Stefan Glück, Carlos L. Arteaga, and Kent Osborne, University of Miami s Sylvester Comprehensive Cancer Center,
More informationBNC105 PHASE II RENAL CANCER TRIAL RESULTS
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
More informationSmall-Cell Lung Cancer Global Clinical Trials Review, H2, 2015
Brochure More information from http://www.researchandmarkets.com/reports/3398017/ Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Description: Small-Cell Lung Cancer Global Clinical Trials
More informationSystemic Therapy for Patients With Advanced HER2-Positive Breast Cancer
Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer CLINICAL PRACTICE GUIDELINE www.asco.org/guidelines/treather2pos American Society of Clinical Oncology. All rights reserved. Introduction
More informationControversies in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment strategies
Annals of Oncology 15 (Supplement 4): iv23 iv29, 2004 doi:10.1093/annonc/mdh901 Controversies in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment strategies V. D Hondt & M. Piccart
More informationLa Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi
La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)
More informationGuidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Crizotinib as 2nd line treatment for patients with anaplastic lymphoma kinase (ALK) positive lung cancer Score The application
More informationNational Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.
Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under
More informationAdjuvant Endocrine Therapy in Breast Cancer: 2015 Update
Adjuvant Endocrine Therapy in Breast Cancer: 2015 Update Shannon Puhalla, MD Director, Breast Cancer Clinical Research Program Magee Womens Cancer Program University of Pittsburgh Cancer Institute Questions
More informationThe Kaplan-Meier Plot. Olaf M. Glück
The Kaplan-Meier Plot 1 Introduction 2 The Kaplan-Meier-Estimator (product limit estimator) 3 The Kaplan-Meier Curve 4 From planning to the Kaplan-Meier Curve. An Example 5 Sources & References 1 Introduction
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More information